Sign In
Buy SMID
$27.14
-1.33 (-4.66%)
At Close: Jul 31, 2026
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
07:00am, Thursday, 30'th Jan 2025
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Wednesday, 29'th Jan 2025
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Wednesday, 29'th Jan 2025
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
08:00am, Wednesday, 29'th Jan 2025
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
08:00am, Wednesday, 29'th Jan 2025
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
07:30am, Wednesday, 29'th Jan 2025
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
07:30am, Wednesday, 29'th Jan 2025
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody thera
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
07:00am, Wednesday, 29'th Jan 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
07:00am, Wednesday, 29'th Jan 2025
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Tuesday, 28'th Jan 2025
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Tuesday, 28'th Jan 2025
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Off
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
07:30am, Thursday, 23'rd Jan 2025
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
Easi-Set Worldwide Signs Building License Agreement with Infrastructure Precast, Inc.
08:30am, Tuesday, 21'st Jan 2025
MIDLAND, VA / ACCESS Newswire / January 21, 2025 / Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation (NASDAQ:SMID), is excited to announce a new licensing agreement with Infrastructure Pre
Why SMID Cap ETFs Make Sense in a Falling-Rate Environment
08:02am, Tuesday, 10'th Dec 2024
Small- and mid-cap (SMID cap) ETFs have seen strong flows recently, making it important that investors fully understand why moving down the cap spectrum can make sense in a falling rate environment. I
Navigate the SMID Cap Space With Active ETFs
01:29pm, Wednesday, 27'th Nov 2024
While many investors seem fixated on the mega cap equities, one would be remiss to ignore the immense potential of SMID caps. There are more than a few reasons why SMID caps currently offer an attract
